Herba Epimedii extraction overcome Rosiglitazone induced bone loss in diabetic rats

Diabetes mellitus patients are more prone to suffer from bone fractures. Herba Epimedii has been demonstrated to be an osteoporosis reducer in the past. However, it is yet uncertain if Herba Epimedii may protect diabetic rats from bone loss when co-administered with rosiglitazone (RSG). This study examines the impact of Herba Epimedii on bone oxidative stress and turnover markers in diabetic rats co-treated with rosiglitazone (RSG). Streptozotocin (STZ) causes diabetics. Wistar albino rats were placed into five groups, each with six rats: control (vehicle therapy), Streptozotocin (diabetes) group, Herba Epimedii group, Rosiglitazone, and Rosiglitazone +Herba Epimedii. Each medication was given by gastric gavage once a day for 35 days. Insulin, oxidative stress, and bone turnover markers were measured in the blood using ELISA assays. Insulin and osteocalcin levels were significantly higher in diabetic rats administered Herba Epimedii than in diabetic control rats. Herba Epimedii may be able to prevent diabetic osteoporosis in RSG-treated diabetic rats by enhancing osteogenesis and lowering bone oxidative stress. The utility of Herba Epimedii as an osteoporosis therapy in diabetic individuals is supported by these findings. Keywords: Herba Epimedii, Diabetes, Osteoporosis, Rosiglitazone

Simultaneous quantification of eurycomanone, epimedin C and icariin in film coated tablets containing Radix Eurycomae longifoliae extract and Herba Epimedii extract using HPLC – DAD

Introduction. This study aimed at developing an HPLC-DAD method for simultaneous determination of eurycomanone (EU), epimedin C (EC) and icariin (IC) in EE tablets containing Radix Eurycomae longifoliae extract and Herba Epimedii extract (EE tablets). Methods. Several HPLC conditions (detection wavelength, mobile phase) and sample preparation conditions (type of solvent, ratios of tablet powder and solvent) were investigated. Results. The optimized HPLC condition employed a Shim-Pack RP18 column and a detection wavelength of 254 nm. The mobile phase consisted of acetonitrile and water containing 0.1% H3PO4 in gradient elution. The method was selective, linear, precise (RSD < 2%) and accurate with recoveries in the range of 98.51–104.58% for EU, 96.22–104.80% for EC and 97.50–104.96% for IC. Conclusion. The method for simultaneous quantification of EU, EC and IC in EE tablets by HPLC – DAD was developed and validated for the first time and could be applied for quality control of EE tablets.

A preliminary strategy for screening the combination of active components based on Bu–Shen–Yi–Qi Decoction for bronchial asthma

Objective: The anti-asthma herbal medicine Bu–Shen–Yi–Qi Decoction (BSYQ Decoction), a combination of three traditional Chinese medicine herbs developed in our lab, has shown demonstrated efficacy in Ovalbumin (OVA)-induced acute bronchial asthma. However, the obscure substances, multiple potential targets and the unclear molecular mechanisms are obstacles to control drug quality, stability and standardization. Multi-component formulae with a clear pharmacodynamic material and specific mechanism are an innovation worth exploring. They may also partly reserve a potential synergistic and additive effect compared with single components extracted from traditional Chinese herbs. This study was designed to select three standard multi-component formulae of the combination of effective components preliminarily based on four effective components [total flavonoids of Herba Epimedii ([Formula: see text]; Astragalus polysaccharide ([Formula: see text]; Astragaloside ([Formula: see text]; and Catalpol ([Formula: see text]] in BSYQ Decoction. Methods: OVA-induced asthmatic murine models were established. A uniform design was applied to select 10 proportions from four target components, and 3 formulae which showed best effect aimed at IFN-[Formula: see text], IL-4 and IgE in the serum respectively were screened based on stepwise regression analysis. Results: According to the regression analysis, Formula I ([Formula: see text]:[Formula: see text]:[Formula: see text]:6:29), Formula II ([Formula: see text]:[Formula: see text]:[Formula: see text]:8:2) and Formula III ([Formula: see text]:[Formula: see text]:[Formula: see text]:[Formula: see text]:50:8:2) are the three potential proper ratios for the new multi-component formula aimed at serum IFN-[Formula: see text], IL-4 and IgE in OVA-induced asthma mice, respectively. Conclusion: Three multi-component formulae derived from BSYQ Decoction could exert anti-inflammatory effect against OVA-induced asthma, which might provide evidences and lay foundations for further study of standard modern Chinese drug for treating asthma based on BSYQ Decoction.